Abstract
Background The drug management of chronic urticaria can be divided into three approaches: (i) blockade of released histamine at the receptor sites; (ii) blockade of histamine release from mast cells; and (iii) blockade of other mediators and possible inflammatory and cellular components. The first approach is the most successful and widely used. It primarily involves the use of H1-antihistamines, although tricyclic antidepressants and H2-antihistamines also have a place.Treatments The usefulness of classic H1-antihistamines, such as hydroxyzine, may be limited by side-effects (most notably, sedation). The four most widely used of the newer antihistamines are loratadine, terfenadine, astemizole and cetirizine. These antihistamines are significantly superior to placebo and have similar efficacies comparable with hydroxyzine. Novel agents and methods, including nifedipine, sulphasalazine and plasmapheresis have been tried with some success in refractory patients.Guidelines If acute cases are inadequately controlled, short-term oral corticosteroids may be added. Systemic corticosteroids are occasionally indicated for the management of severe acute urticaria, severe serum sickness, pressure urticaria or urticarial vasculitis, or to break the cycle of a resistant case, but have no place in regular therapy for chronic urticaria. For those with severe acute urticaria with signs of respiratory distress, possible treatments include subcutaneous epinephrine, systemic corticosteroids and intramuscular H1-antihistamines. Patients with chronic urticaria inadequately controlled on H1-antihistamines alone may benefit from the addition of a classic antihistamine, a tricyclic antidepressant or an H2-antihistamine. A short course of systemic corticosteroids may help those with severe chronic refractory disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have